Biogen to Spin Off Hemophilia Unit

Biogen Inc. said it plans to spin off its hemophilia business as a publicly traded company so the biotechnology company can increase its focus on neurology drugs.
Source: WSJ.com: Health - Category: Pharmaceuticals Tags: FREE Source Type: news